FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362730611> ?p ?o ?g. }

• W4362730611 endingPage "836" @default.
• W4362730611 startingPage "824" @default.
• W4362730611 abstract ": Surgical resection followed by adjuvant cisplatin-based chemotherapy is the recommended treatment for patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC). Even with the best management, recurrence is common and increases with disease stage (stage I: 26–45%; stage II: 42–62%; stage III: 70–77%). For patients with metastatic lung cancer and tumours that harbour epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKIs) have improved survival. Their effectiveness in advanced stages of NSCLC raises the possibility that these agents may improve outcomes for patients with resectable EGFR-mutated lung cancer. In the ADAURA study, adjuvant osimertinib provided a significant improvement in disease-free survival (DFS) and reduced central nervous system (CNS) disease recurrence in patients with resected stage IB–IIIA EGFR-mutated NSCLC, with or without prior adjuvant chemotherapy. To reap the maximum benefits of EGFR-TKIs for patients with lung cancer, the early and rapid identification of EGFR mutations [and other oncogenic drivers, such as programmed cell death-ligand 1 (PD-L1), with matched targeted therapies] in diagnostic pathologic specimens has become essential. To ensure patients receive the most appropriate treatment, routine, comprehensive histological, immunohistochemical, and molecular analyses (with multiplex next generation sequencing) should be undertaken at the time of diagnosis. The potential for personalised treatments to cure more patients with early-stage lung cancer can only be realised if all therapies are considered when the care plan is formulated, by the multi-specialty experts managing patients. In this review, we discuss the progress and prospects for adjuvant treatments as part of a comprehensive plan of care for patients with resected stages I–III EGFR-mutated lung cancer, and explore how the field could go beyond DFS and overall survival to make cure a more frequent outcome of treatment in patients with resected EGFR-mutated lung cancer." @default.
• W4362730611 created "2023-04-10" @default.
• W4362730611 creator A5039791495 @default.
• W4362730611 creator A5063300526 @default.
• W4362730611 creator A5081110935 @default.
• W4362730611 date "2023-04-01" @default.
• W4362730611 modified "2023-10-14" @default.
• W4362730611 title "Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives" @default.
• W4362730611 cites W1965370740 @default.
• W4362730611 cites W1971159432 @default.
• W4362730611 cites W2009775937 @default.
• W4362730611 cites W2029122407 @default.
• W4362730611 cites W2040299716 @default.
• W4362730611 cites W2040561412 @default.
• W4362730611 cites W2065437747 @default.
• W4362730611 cites W2082148749 @default.
• W4362730611 cites W2088117088 @default.
• W4362730611 cites W2088540000 @default.
• W4362730611 cites W2091912934 @default.
• W4362730611 cites W2101365737 @default.
• W4362730611 cites W2101569260 @default.
• W4362730611 cites W2104504726 @default.
• W4362730611 cites W2108890516 @default.
• W4362730611 cites W2122175831 @default.
• W4362730611 cites W2123873666 @default.
• W4362730611 cites W2129360604 @default.
• W4362730611 cites W2149733252 @default.
• W4362730611 cites W2152429112 @default.
• W4362730611 cites W2153169173 @default.
• W4362730611 cites W2153979476 @default.
• W4362730611 cites W2160766792 @default.
• W4362730611 cites W2160889088 @default.
• W4362730611 cites W2163351155 @default.
• W4362730611 cites W2210071992 @default.
• W4362730611 cites W2231734012 @default.
• W4362730611 cites W2237969201 @default.
• W4362730611 cites W2268267848 @default.
• W4362730611 cites W2300932108 @default.
• W4362730611 cites W2470068589 @default.
• W4362730611 cites W2491982852 @default.
• W4362730611 cites W2530508394 @default.
• W4362730611 cites W2560717039 @default.
• W4362730611 cites W2569936743 @default.
• W4362730611 cites W2607970143 @default.
• W4362730611 cites W2609243345 @default.
• W4362730611 cites W2609444947 @default.
• W4362730611 cites W2614086748 @default.
• W4362730611 cites W2768989095 @default.
• W4362730611 cites W2770828094 @default.
• W4362730611 cites W2784586990 @default.
• W4362730611 cites W2884459417 @default.
• W4362730611 cites W2887416920 @default.
• W4362730611 cites W2888297236 @default.
• W4362730611 cites W2888877308 @default.
• W4362730611 cites W2899025211 @default.
• W4362730611 cites W2904370794 @default.
• W4362730611 cites W2911174524 @default.
• W4362730611 cites W2936767216 @default.
• W4362730611 cites W2964623804 @default.
• W4362730611 cites W2975758168 @default.
• W4362730611 cites W2990041408 @default.
• W4362730611 cites W3003499321 @default.
• W4362730611 cites W3025067959 @default.
• W4362730611 cites W3035493769 @default.
• W4362730611 cites W3085851693 @default.
• W4362730611 cites W3087210493 @default.
• W4362730611 cites W3091781059 @default.
• W4362730611 cites W3111438285 @default.
• W4362730611 cites W3111473818 @default.
• W4362730611 cites W3134864632 @default.
• W4362730611 cites W3137057543 @default.
• W4362730611 cites W3163840789 @default.
• W4362730611 cites W3176721534 @default.
• W4362730611 cites W3184279932 @default.
• W4362730611 cites W3186743916 @default.
• W4362730611 cites W3189383967 @default.
• W4362730611 cites W3192462534 @default.
• W4362730611 cites W3195364627 @default.
• W4362730611 cites W3199241644 @default.
• W4362730611 cites W3211122929 @default.
• W4362730611 cites W4210992155 @default.
• W4362730611 cites W4225635218 @default.
• W4362730611 cites W4226360102 @default.
• W4362730611 cites W4226382697 @default.
• W4362730611 cites W4239827677 @default.
• W4362730611 cites W4280558216 @default.
• W4362730611 cites W4290879631 @default.
• W4362730611 cites W4293795419 @default.
• W4362730611 cites W4307848518 @default.
• W4362730611 cites W4318693852 @default.
• W4362730611 cites W848808121 @default.
• W4362730611 cites W3129029771 @default.
• W4362730611 doi "https://doi.org/10.21037/tlcr-22-723" @default.
• W4362730611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37197636" @default.
• W4362730611 hasPublicationYear "2023" @default.
• W4362730611 type Work @default.
• W4362730611 citedByCount "1" @default.
• W4362730611 countsByYear W43627306112023 @default.

• next